Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
about
Seroprevalence and risk factors of Kaposi's sarcoma-associated herpesvirus infection among the general Uygur population from south and north region of Xinjiang, ChinaPosttransplantation malignancy in a patient presenting with weight loss and changed bowel habits: a case reportTherapy Insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and managementTarget of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsHuman Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulatorAdvances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomasTargeting the mTOR signaling network for cancer therapyRapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signalingAdapting the Stress Response: Viral Subversion of the mTOR Signaling PathwayUpdate on kidney transplantation in human immunodeficiency virus infected recipientsNeoplastic disease after liver transplantation: Focus on de novo neoplasmsSystemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsSkin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer?Rapalogs in cancer prevention: anti-aging or anticancer?Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancerEverolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateLifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycinRapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug.Targeting the phosphoinositide 3-kinase pathway in cancerTuberous Sclerosis Complex Associated with Vascular Anomalies or Overgrowth.Outcomes of kidney transplantation in HIV-infected recipientsMolecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not".Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects.The pros and the cons of mTOR inhibitors in kidney transplantation.Validation of anti-aging drugs by treating age-related diseases.Growth and aging: a common molecular mechanism.The PIK3CA gene as a mutated target for cancer therapy.mTORC1 activation in childhood ependymoma and response to sirolimus.KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine.Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus.Update on HHV-8-Associated MalignanciesMolecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.From rapalogs to anti-aging formula.Hormesis and Defense of Infectious Disease.Non-AIDS associated Kaposi's sarcoma: clinical features and treatment outcomeAmplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi's sarcomaInhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency.
P2860
Q21245098-46FEDA93-642B-41A9-A89E-C5BE05F4F6FFQ21261410-F9346AD7-FC95-4066-8281-B7A8A0D6E0CDQ22251070-FF06C807-F96E-4AFC-968C-45A4B5A428FBQ24246340-24A754CC-1A85-427F-9916-EEBB156CA8CEQ24609227-AE71F8DA-CA10-4144-B715-BD2620BE32B4Q24623371-4328A645-84EA-4E06-99D5-E9FD6E655BA5Q24658269-2F68E90C-7AD8-4375-8C37-03B957411613Q24658334-95D4F7C9-D2FC-4848-8988-85A743767214Q24673299-126138A8-F26C-4DCE-B3BC-B75CE5D3DF93Q26700049-22AD3DB3-6E59-4227-995A-412FABB0D7C3Q26741544-9F6F8D49-FEF1-40E1-B0EB-AD248B40A6B9Q26798306-390CB5E6-D9B4-4AC7-8047-19EE56E90569Q26823023-A3A72B34-6386-4AAD-8C49-E735735BC738Q26851436-27B0C080-B453-42E2-8245-0A74641F63C0Q26866151-FEDA0BF9-211A-4FA1-937F-7D9C24CBC878Q27020978-DA376F8B-9213-4D13-A749-E703CA56F68DQ28067598-EF82B6D6-575A-4C1F-9A98-266B0348450EQ28307873-4DDE27F2-9647-4C22-99B1-80A123356C66Q28476740-17A20387-6E19-45BD-A2BC-0D2E2CDAFBF5Q29615809-CC6F99F4-470A-4DAF-9F0E-3C0C40FE9C8EQ30248734-E66E1E2E-EB44-4CB3-98DC-CBDFD4A65EFBQ30432292-614FBB3E-C0A3-4AB4-A7FF-49E6A130B407Q33280039-710D747B-8113-424B-9687-3BD0111DB357Q33299027-FE5D9CBB-45FE-4308-96CF-09AFDE6F6A70Q33316872-A61A9E71-59F8-456D-87B6-26967F72F332Q33393707-2D0F5C89-A8C9-4B39-8229-F200E4F0403DQ33412367-120C40F6-7BBA-440A-930A-F30AAB5D8FF4Q33588700-7A06A497-B994-4F4E-9A1D-89476282281AQ33588716-287FE0AF-50ED-4D98-9A83-E47C6813510EQ33699378-C9897C43-BA5E-4BD3-976E-07804816BF17Q33746501-CAC8180F-2011-4919-BD08-5C982681760BQ33761091-42D8F6A5-BB53-4F61-A70B-9BFF16402B9DQ33793543-9496056E-C8C6-4D4F-A36F-FABF824A6640Q33814153-3C763FFF-3BFA-4148-AF9D-3231DCE55467Q33819076-525666A8-73AC-4EC0-A56F-4E8F6509C754Q33829205-8F3BBBE5-372E-45EB-AAA6-097E474A1183Q33838971-04B1FE42-09C4-4F8A-AE28-D1371E48F0ADQ33886847-53EA000B-6400-430D-85CD-3C60C0DA1DC7Q33895137-AB620FBD-D40F-442E-8BA7-F72E1C2E3CD7Q33923893-EC558841-3028-423E-A1ED-9EC0BAFFA9B7
P2860
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@ast
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@en
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@nl
type
label
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@ast
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@en
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@nl
prefLabel
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@ast
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@en
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@nl
P2093
P356
P1476
Sirolimus for Kaposi's sarcoma in renal-transplant recipients.
@en
P2093
Antonella Loverre
Antonio Schena
Barbara Infante
Elena Ranieri
Francesco Paolo Schena
Giovanni Stallone
Giulio Maggio
Giuseppe Grandaliano
Loreto Gesualdo
Salvatore Di Paolo
P304
P356
10.1056/NEJMOA042831
P407
P577
2005-03-01T00:00:00Z